Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

Alice Tzeng,C. Marcela Diaz-Montero,Patricia Rayman,Jin S. Kim,Paul G. Pavicic,James H. Finke,Pedro C. Barata,Marcelo Lamenza,Sarah Devonshire,Kim Schach,Hamid Emamekhoo,Marc S. Ernstoff,Christopher J. Hoimes,Brian I. Rini,Jorge A. Garcia,Timothy D. Gilligan,Moshe Chaim Ornstein,Petros Grivas

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

2018

Alice Tzeng
C. Marcela Diaz-Montero
Patricia Rayman
Jin S. Kim
Paul G. Pavicic
James H. Finke
Pedro C. Barata
Marcelo Lamenza
Sarah Devonshire
Kim Schach
Hamid Emamekhoo
Marc S. Ernstoff
Christopher J. Hoimes
Brian I. Rini
Jorge A. Garcia
Timothy D. Gilligan
Moshe Chaim Ornstein
Petros Grivas

Background The identification of prognostic and/or predictive biomarkers for response to immune checkpoint inhibitors (ICI) could help guide treatment decisions.

Keywords:

Immunology
Cancer research
Metastatic Urothelial Carcinoma
Biomarker (medicine)
Medicine
Immune checkpoint
Peripheral blood mononuclear cell
Avelumab
CD8
Pembrolizumab
Immune system
Atezolizumab
CTL*

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations